Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate

Ann N Y Acad Sci. 1991:622:302-6. doi: 10.1111/j.1749-6632.1991.tb37875.x.

Authors

P Fioretti¹, M Gambacciani, A Spinetti, A Cagnacci, A M Paoletti, R Felipetto, G B Melis

Affiliation

¹ Department of Obstetrics and Gynecology, University of Pisa, School of Medicine, Italy.

PMID: 1829595
DOI: 10.1111/j.1749-6632.1991.tb37875.x

No abstract available

MeSH terms

Administration, Cutaneous
Administration, Oral
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Endometrium / drug effects*
Endometrium / physiology
Estradiol / administration & dosage
Estradiol / pharmacology
Estradiol / therapeutic use*
Female
Humans
Medroxyprogesterone / administration & dosage
Medroxyprogesterone / analogs & derivatives*
Medroxyprogesterone / pharmacology
Medroxyprogesterone / therapeutic use
Medroxyprogesterone Acetate
Middle Aged
Osteoporosis / drug therapy
Osteoporosis / prevention & control*

Substances

Antineoplastic Agents
Estradiol
Medroxyprogesterone Acetate
Medroxyprogesterone